Literature DB >> 820247

Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus.

M Kitahara, V K Seth, G Medoff, G S Kobayashi.   

Abstract

Amphotericin B in combination with 5-fluorocytosine was synergistic against three clinical isolates of Aspergillus fumigatus and one of three clinical isolates of A. flavus. Amphotericin B in combination with rifampin was synergistic against all six clinical isolates of Aspergillus tested. The levels of 5-fluorocytosine and rifampin required for synergism were higher than clinically achievable concentrations when measurements of synergism were based on visual turbidity; but when the effects of the drugs were measured by inhibition of ribonucleic acid synthesis or dry-weight increase, much lower concentrations were effective.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 820247      PMCID： PMC429650          DOI： 10.1128/AAC.9.6.915

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Growth of the yeastlike phase of Histoplasma capsulatum in a fluid medium.

Authors:  S B SALVIN
Journal:  J Bacteriol       Date:  1950-02       Impact factor: 3.490

2.  Effect of 5-fluorocytosine and amphotericin B on Candida albicans infection in mice.

Authors:  S Rabinovich; B D Shaw; T Bryant; S T Donta
Journal:  J Infect Dis       Date:  1974-07       Impact factor: 5.226

3.  The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis.

Authors:  E R Block; J E Bennett
Journal:  Proc Soc Exp Biol Med       Date:  1973-02

4.  RNA metabolism during morphogenesis in Histoplasma capsulatum.

Authors:  S S Cheung; G S Kobayashi; D Schlessinger; G Medoff
Journal:  J Gen Microbiol       Date:  1974-06

5.  Cure of Aspergillus ustus endocarditis on a prosthetic valve.

Authors:  J Carrizosa; M E Levison; T Lawrence; D Kaye
Journal:  Arch Intern Med       Date:  1974-03

6.  Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms.

Authors:  G Medoff; M Comfort; G S Kobayashi
Journal:  Proc Soc Exp Biol Med       Date:  1971-11

7.  Antimicrobial susceptibility testing of six clinical isolates of Aspergillus.

Authors:  M Kitahara; V K Seth; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

8.  Chemotherapeutic activity of 5-fluorocytosine and amphotericin B against Candida albicans in mice.

Authors:  E Titsworth; E Grunberg
Journal:  Antimicrob Agents Chemother       Date:  1973-09       Impact factor: 5.191

9.  Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum.

Authors:  G S Kobbayashi; G Medoff; D Schlessinger; C N Kwan; W E Musser
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

10.  Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism).

Authors:  G Medoff; G S Kobayashi; C N Kwan; D Schlessinger; P Venkov
Journal:  Proc Natl Acad Sci U S A       Date:  1972-01       Impact factor: 11.205
View more
  24 in total

Review 1.  Antifungal activity of nonantifungal drugs.

Authors:  J Afeltra; P E Verweij
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-26       Impact factor: 3.267

2.  In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.

Authors:  Eric Dannaoui; Javier Afeltra; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 3.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine.

Authors:  J Arroyo; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

5.  In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp.

Authors:  C E Hughes; C Harris; J A Moody; L R Peterson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

Review 6.  Aspergillosis of the CNS in a pediatric liver transplant recipient: case report and review.

Authors:  M Green; E R Wald; A Tzakis; S Todo; T E Starzl
Journal:  Rev Infect Dis       Date:  1991 Jul-Aug

7.  Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans.

Authors:  I J Sud; D S Feingold
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

8.  Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

Review 9.  Antifungal agents used in systemic mycoses. Activity and therapeutic use.

Authors:  J R Graybill; P C Craven
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

10.  Problems in antifungal chemotherapy.

Authors:  D A Stevens
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.